Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Anti-IL5 Non-Responders
NCT03470311Phase 3Completed
- Sponsor
- McMaster University
- Start
- Apr 2018
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), sponsored by McMaster University. Started Apr 2018; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03470311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470311.